Fig. 4From: An optimal window of platelet reactivity by LTA assay for patients undergoing percutaneous coronary intervention1-year Adverse Events in Groups of Different Level of PLADP. Patients were stratified into groups of NOPR (25.5–37.4%), HOPR (≥37.5%) and LOPR (< 25.5%). ** represents P < 0.001 for bleeding events compared with the NOPR group. †† represents P < 0.001 for net adverse clinical events compared with the NOPR group. PLADP, ADP induced platelet aggregation; NOPR, normal on-treatment platelet reactivity; HOPR, high on-treatment platelet reactivity; LOPR, low on-treatment platelet reactivityBack to article page